Efficacy and safety of single agent pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in hormone refractory prostate cancer after failure of taxane-based therapy Meeting Abstract
| Authors: | Agus, D. B.; Sweeney, C. J.; Morris, M.; Mendelson, D.; McNeel, D. G.; Ahmann, F.; Wang, J.; Derynck, M. K.; Kattan, M. W.; Scher, H. I. |
| Abstract Title: | Efficacy and safety of single agent pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in hormone refractory prostate cancer after failure of taxane-based therapy |
| Meeting Title: | 41st Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 23 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2005 May 13-17 |
| Meeting Location: | Orlando, FL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2005-06-01 |
| Start Page: | 408S |
| Language: | English |
| ACCESSION: | WOS:000230326602453 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2005.23.16_suppl.4624 |
| Notes: | --- - Meeting Abstract: 4624 - 41st Annual Meeting of the American-Society-of-Clinical-Oncology - MAY 13-17, 2005 - Orlando, FL - S - Part 1 - "Source: Wos" |
Altmetric
Citation Impact
BMJ Impact Analytics
